BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

November 6, 2014

Enables BIND to Develop Product Candidates Utilizing Merck Compounds

T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results

T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results

November 4, 2014

 IPO and First FDA Clearances Mark Beginning of Commercial Activity

LEXINGTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the third quarter ended September 30, 2014. Highlights of the quarter included:

Mascoma Completes the Sale of its Yeast Business to Lallemand Inc.

Mascoma Completes the Sale of its Yeast Business to Lallemand Inc.

November 4, 2014

Waltham, MA and Montreal, QC – November 4, 2014 – Mascoma Corporation, a leader in advanced bioconversion products, announced today that it has completed the sale of its yeast business to Lallemand Inc., a privately owned company that researches, develops, produces and markets yeasts, bacteria, and related products. As part of the transaction, Lallemand has acquired the Mascoma company name and trademarks, all of its proprietary and patented yeast strains and associated technologies, as well as its entire research and development team located at its facility in Lebanon, NH.

BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical Officer

BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical Officer

November 4, 2014

— BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Hagop Youssoufian, M.Sc., M.D., as Chief Medical Officer. In this position, Dr. Youssoufian will be responsible for overseeing the clinical development and operations of BIND’s internal pipeline. Edward Schnipper, M.D., who has been serving as interim CMO since January 2014, will continue in an advisory role.

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease

November 3, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease.

Visterra Announces Additions to its Management Team and Board of Directors

Visterra Announces Additions to its Management Team and Board of Directors

October 31, 2014

– Veteran Biotech Executive José M. Trevejo, MD, PhD, to Head Clinical Development and Regulatory Affairs; Industry Leader Akshay Vaishnaw, MD, PhD, FRCP Elected to Board –

Novomer Announces First Commercial Adoption of Converge® Polyols for Polyurethane Adhesives

Novomer Announces First Commercial Adoption of Converge® Polyols for Polyurethane Adhesives

October 27, 2014

WALTHAM, Mass., October 27, 2014 - Novomer Inc., a sustainable materials company pioneering a family of high-performance polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), has announced that Jowat AG, a leading supplier of industrial adhesives headquartered in Germany, is the first to commercially adopt Novomer’s new Converge® polypropylene carbonate (PPC) polyols for use in polyurethane hot melt adhesive applications.

Nielsen Acquires Affinnova

Nielsen Acquires Affinnova

October 30, 2014

New York – Oct. 30, 2014 – Nielsen, a leading global provider of information and insights into what consumers watch and buy, has recently completed its acquisition of Affinnova, an international media and marketing research firm. The Affinnova team will become part of Nielsen’s Innovation Practice area, expanding the team globally and accelerating delivery of a suite of digitally-enabled, innovative solutions for every step of the new product development and activation process.

Syros Pharmaceuticals Closes $53 Million Series B Financing

Syros Pharmaceuticals Closes $53 Million Series B Financing

October 27, 2014

 - Includes Leading Public and Healthcare-Focused Funds -

- Proceeds Will Accelerate Gene Control Programs and Platform -

The TransMedics® Organ Care System (OCS™) Heart Technology Was Used to Perform The World’s First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent’s Hospital in Sydney, Australia

The TransMedics® Organ Care System (OCS™) Heart Technology Was Used to Perform The World’s First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent’s Hospital in Sydney, Australia

October 24, 2014

Andover, Mass. - October 24, 2014  - TransMedics announces that its OCS™ Heart technology was used successfully to preserve and assess the world’s first series of three successful adult heart transplant procedures from hearts donated from donors after circulatory death (DCD) by the St. Vincent’s Hospital Heart Transplant team. All patients who received these groundbreaking transplants have recovered very well.